Statement: the primary trial records two different types of pain in its adverse events, in the abdomen and chest area, the secondary trial does not record any types of pain in its participants. 
Primary_evidence: Adverse Events 1:   Total: 8/29 (27.59%)   Hemorrhage - Nose 1/29 (3.45%)   Left Ventricular Systolic Dysfunction 1/29 (3.45%)   Vomiting 1/29 (3.45%)   Esophagitis 1/29 (3.45%)   Pain - Abdomen 1/29 (3.45%)   Pain - Chest 1/29 (3.45%)   Infection - Skin 1/29 (3.45%)   Infection - Sepsis 2/29 (6.90%)   Creatinine 1/29 (3.45%)   Wound Complication, Non-Infectious 1/29 (3.45%)
Secondary_evidence: Adverse Events 1:   Total: 8/29 (27.59%)   Leukopenia  [1]1/29 (3.45%)   Thrombocytopenia  [1]1/29 (3.45%)   Abscess  [1]1/29 (3.45%)   Breast Abscess 1/29 (3.45%)   Fever/Sepsis  [1]1/29 (3.45%)   Neutropenic Fever  [2]1/29 (3.45%)   Peripheral Neuropathy  [1]1/29 (3.45%)   Seizure/Syncope  [1]1/29 (3.45%)   Hematuria  [1]1/29 (3.45%)   UTI  [1]1/29 (3.45%)   Shortness of breath  [1]1/29 (3.45%)